OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - OPKO Health reported revenue of $183.6 million for the quarter ended December 2024, reflecting a year-over-year increase of 0.9% and surpassing the Zacks Consensus Estimate of $155.14 million by 18.35% [1] - The company achieved an EPS of $0.01, a significant improvement from -$0.09 in the same quarter last year, resulting in an EPS surprise of 109.09% against the consensus estimate of -$0.11 [1] Revenue Breakdown - Revenue from the transfer of intellectual property and other sources was $43.10 million, exceeding the average estimate of $14.89 million by analysts, marking a year-over-year increase of 193.2% [4] - Revenue from products was reported at $37.40 million, which fell short of the average estimate of $42.96 million, representing a year-over-year decline of 13% [4] - Revenue from services amounted to $103.10 million, slightly above the estimated $97.29 million, but showed a year-over-year decrease of 17% [4] Stock Performance - OPKO Health's shares have returned +10.7% over the past month, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]